Project Grant K01DA062708

Award Date 6/15/25
Completion Date 5/31/30
Dollars Obligated $177K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
This $310,319 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support the University of Louisville in conducting formative research to develop a motivation-based adolescent vaping typology to inform the development of tailored cognitive behavioral e-cigarette cessation interventions. The key objectives are to: 1) identify different types of adolescent e-cigarette users based on their motivations for use, 2)...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $241,500 to Duke University to examine the use of very low nicotine content (VLNC) cigarettes as a means to improve smoking cessation outcomes among individuals with opioid use disorder and chronic pain. The research will employ a randomized design to evaluate the effects of VLNC cigarettes versus normal nicotine content cigarettes on smoking...
This $1,197,896 Project Grant was awarded on May 1, 2025 by the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077). The grant funds a 5-year longitudinal study to assess the impact of electronic nicotine delivery system (ENDS) product characteristics on use behaviors and abuse liability among young adult ENDS users (ages 18-25). The study employs traditional survey methods combined...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $423,447 to Brown University to investigate the impact of social-contextual stressors on smoking cessation and relapse among socioeconomically disadvantaged young adults (SDYA). The project aims to gain an in-depth understanding of how specific social-contextual stressors influence smoking behaviors in SDYA through a mixed-methods approach,...
This $619,175 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a Type 1 hybrid effectiveness-implementation trial at the Medical University of South Carolina. The trial aims to evaluate the effectiveness of an e-cigarette switching approach compared to standard care in helping oncology outpatients who smoke but refuse traditional tobacco treatment. Key objectives include assessing rates of complete...
This $189,500 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs aims to determine the extent to which cardiovascular disease (CVD) affects individuals with opioid use disorder (OUD) and how patients, providers, and payers can prevent CVD in this population. The key objectives are to: 1) examine the relationship between OUD and time to major adverse cardiovascular events (MACE), 2) identify barriers and...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) will support research to identify and address misperceptions about the relative risks of e-cigarettes compared to traditional cigarettes. The $171,742 award to Rutgers, The State University of New Jersey aims to: 1) identify common belief patterns about cigarette and e-cigarette harms, 2) develop...
The National Institutes of Health (NIH), through the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), awarded a $669,321 project grant to the Regents of the University of California at Riverside (UC Riverside). The grant supports a 1-year study to characterize new and emerging ingredients, acids, toxicants, and indicators of non-tobacco nicotine in electronic cigarette (e-cigarette) products. The research will involve: Analyzing 600 commercial...
This federal Project Grant award of $549,555.45 from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) supports a cross-sectional study to investigate the exposure and toxicity of chemical constituents of concern, namely metals and aldehydes, as well as the pulmonary health effects, including inflammation, of using new and emerging electronic cigarette (e-cigarette) devices among...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $265,239 to the University of North Carolina at Chapel Hill to evaluate the chemical composition and toxicity of vaping products containing alternative nicotine formulations, such as 6-methyl nicotine. The key objectives are to: 1) Analyze the chemical composition and metabolism of 6-methyl nicotine and nicotinamide vaping products before...

ELECTRONIC CIGARETTES AS A HARM REDUCTION STRATEGY AMONG PEOPLE WITH OPIOID USE DISORDER ON BUPRENORPHINE - PROJECT SUMMARY/ABSTRACT CANDIDATE AND CAREER DEVELOPMENT: I AM AN ASSISTANT PROFESSOR AT CLEMSON UNIVERSITY, PROPOSING A K01 CAREER DEVELOPMENT PLAN AND RESEARCH PLAN TO PREPARE ME TO BECOME AN INDEPENDENT CLINICAL RESEARCH SCIENTIST AND LEADER IN DEVELOPING AND IMPLEMENTING INNOVATIVE AND FEASIBLE ELECTRONIC CIGARETTE (EC) PROTOCOLS ACROSS CLINICAL SETTINGS TO REDUCE THE COMBUSTIBLE CIGARETTE (CC) BURDEN AMONG PEOPLE WITH OPIOID USE DISORDER (OUD) ON BUPRENORPHINE. THIS PROPOSAL BUILDS ON MY EXPERTISE IN NICOTINE AND OPIOID RESEARCH AND EXTENDS IT IN IMPORTANT WAYS. THE GOAL OF THE CAREER DEVELOPMENT PLAN FOCUSES ON SIX SKILL AREAS: (1) QUALITATIVE METHODS, (2) QUANTITATIVE METHODS, (3) ECOLOGICAL MOMENTARY ASSESSMENT (EMA), (4) TOBACCO REGULATORY SCIENCE, (5) GRANT WRITING, AND (6) LEADERSHIP SKILLS. MENTORSHIP TEAM: THE PROPOSED MENTORSHIP TEAM IS TRULY MULTIDISCIPLINARY, WITH BACKGROUNDS IN ADDICTION MEDICINE, PUBLIC HEALTH, PSYCHOLOGY, AND BIOSTATISTICS. EACH MENTOR WILL CONTRIBUTE DISTINCTIVE EXPERTISE TO FACILITATE MY PROGRESSION AS AN INDEPENDENT CLINICAL RESEARCHER. ALL PROPOSED MENTORS HAVE PREVIOUS EXPERIENCE MENTORING SUCCESSFUL MENTEES OR K AWARDEES, WITH EXCEPTIONAL RECORDS OF SCIENTIFIC PUBLICATIONS AND EXTRAMURAL GRANT FUNDING. RESEARCH STRATEGY: EVIDENCE SUPPORTS THE USE OF EC IN REDUCING THE NUMBER OF CIGARETTES SMOKED PER DAY (CPD) OR SWITCHING AWAY FROM CC AMONG ADULTS IN THE GENERAL POPULATION. HOWEVER, PEOPLE WITH OUD ARE UNDERREPRESENTED IN SUCH STUDIES. EC FLAVOR AND USE FREQUENCY MAY INFLUENCE SWITCHING AND REDUCING CPD IN PEOPLE WITHOUT OUD. ADULT CC SMOKERS PREFER SWEET FLAVORS TO TOBACCO FLAVORS, AND COOLING FLAVORS MAY FURTHER ENHANCE THE SENSORY EXPERIENCE OF SWEET FLAVORS. USE OF FLAVORED EC, OTHER THAN TOBACCO, HAS BEEN LINKED TO AN INCREASED LIKELIHOOD OF REDUCING CPD OR SWITCHING TO EC AMONG CC SMOKERS WITHOUT OUD. TO OUR KNOWLEDGE, NO STUDY HAS SYSTEMATICALLY TESTED THE IMPACT OF EC FLAVOR AND PATTERNS OF EC USE ON HARM REDUCTION MILESTONES (E.G., CPD REDUCTION, SWITCHING) AMONG PEOPLE WITH OUD. IN A THREE-GROUP RANDOMIZED CONTROLLED TRIAL (RCT), EXCLUSIVE CC USERS (N=90) WITH OUD ON BUPRENORPHINE, WHO ARE NOT INTERESTED IN QUITTING, WILL BE RECRUITED ACROSS RURAL AND URBAN OUTPATIENT SETTINGS. THESE PARTICIPANTS WILL RECEIVE COUNSELING AND BE RANDOMLY ASSIGNED TO RECEIVE A 12-WEEK SUPPLY OF SWEET-COOLING, SWEET NON-COOLING, OR TOBACCO-FLAVORED EC. ECOLOGICAL MOMENTARY ASSESSMENT (EMA) METHODOLOGY WILL ENABLE US TO EXAMINE PATTERNS OF EC USE ASSOCIATED WITH IMPORTANT HARM REDUCTION MILESTONES. THIS K01 AIMS TO OFFER EXPERTISE IN ADVANCED QUANTITATIVE STATISTICS, EMA, QUALITATIVE RESEARCH, GRANT WRITING, AND LEADERSHIP DEVELOPMENT, ALONGSIDE A MENTORED RESEARCH EXPERIENCE TO ACHIEVE THE FOLLOWING SPECIFIC AIMS: (1)TESTING THE EFFECT OF EC FLAVORS ON CPD REDUCTION, SWITCHING, AND OTHER HARM REDUCTION MILESTONES; (2) CHARACTERIZING RATES AND PATTERNS ASSOCIATED WITH HARM REDUCTION MILESTONES; (3) IDENTIFYING BARRIERS AND FACILITATORS IN IMPLEMENTING AND MAINTAINING THE EC PROTOCOL.

Posted 6/12/25, 12:00 AM